| Project/Area Number |
20K17454
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54020:Connective tissue disease and allergy-related
|
|---|
| Research Institution | Iwate Medical University (2023)
Tokai University (2020-2022) |
|---|
Principal Investigator |
Hosono Yuji 岩手医科大学, 医学部, 特任准教授 (60868090)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 自己抗体 / 炎症性筋疾患 / 悪性腫瘍 / 自己免疫 / 筋炎 / 特発性炎症性筋疾患 / 免疫沈降法 / 皮膚筋炎 / 多発性筋炎 / 間質性肺炎 |
|---|
| Outline of Research at the Start |
本研究では、特発性炎症性筋疾患症例の血清を用いて、既知の筋炎特異自己抗体陰性症例を対象に、筋疾患を早期に診断するためのバイオマーカーとしての新規自己抗体を蛋白免疫沈降法によって探索し、その臨床的特徴や自己抗体の有する病原性の探索を行う。また、自己抗体測定方法を確立し臨床応用を行うことでIIMの早期診断，病型分類，治療法の選択や病態解明につなげることを目的とする。
|
| Outline of Final Research Achievements |
In this study, we investigated the novel autoantibodies in Japanese inflammatory muscle disease patient and the clinical significance of anti-SP4 antibodies, a novel autoantibody discovered by the applicant(Ann Rheum Dis.2023;82:246-252.). Among DM patients, 55% of anti-Sp4 autoantibodies were detected in patients with anti- anti-TIF1γ, 36% were in anti-MDA5 and 18% were in anti-Mi-2 autoantibodies. None of anti-SP4 autoantibody-positive DM patients had cancer. Among anti-TIF1γ-positive DM patients, none of patients with coexisting anti-Sp4 had cancer, while 60% of those without anti-SP4 had (0% vs. 60%; p< 0.05, Chi-squared test). In this study, anti-SP4 autoantibodies were frequency detected in PM/DM patients, and none of anti-SP4 autoantibody-positive DM patients had cancer. Coexisting of anti-SP4 autoantibodies may reduce the risk of malignancy in IIM patients, and screening for anti-SP4 autoantibodies is recommended at the diagnosis of IIM.
|
| Academic Significance and Societal Importance of the Research Achievements |
炎症性筋疾患(IIM)は筋組織のみならず皮膚、肺、関節など全身に炎症がおよぶ自己免疫疾患で、初発症状、臨床経過、病態など様々な形式をとるが、診断・治療開始にあたっては併存疾患のスクリーニングが重要である。中でも悪性腫瘍は治療方針の決定や患者予後に大きく関わることから、IIM診断時には特に入念な精査が求められる。患者血清中に高頻度で検出される自己抗体は早期段階での診断・病型分類、さらには治療反応・予後予測に基づく治療方針の早期決定が可能となるが、筆者らが発見した抗Sp4抗体の検出は悪性腫瘍のリスクを大きく下げることが示され、IIMにおける悪性腫瘍との病態及び臨床的意義の更なる探究が期待される。
|
